Parabilis Medicines, Inc.
Parabilis Medicines is a Cambridge, Massachusetts-based biopharmaceutical company developing helical peptide medicines for diseases. Its Helicon platform supports discovery of peptides designed to engage proteins that have been difficult to target with drugs. The company’s programs include inhibitors of intracellular protein interactions, targeted protein degraders and radiopharmaceuticals. Its clinical pipeline includes FOG-001, a beta-catenin inhibitor that blocks TCF activity and is being developed for cancer treatment.
No SEC Form 4 filings for $PBLS in the last 30 days.
See all $PBLS insider activity →Canaccord Genuity initiated coverage of Parabilis Medicines with a Buy rating and a $39 price target, implying a 36.7% upside from the Nov 6 close of $28.53.
Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 30, 2026, Parabilis Medicines, Inc. (the “Company”) and LS 400/500 CDP, LLC (the “Landlord”) entered into a Third Amendment of Lease (the “Amendment”), which amends certain provisions of that certain Lease Agreement
Parabilis reported a 72% response rate for its drug, comparing it to published data of 41% for nirogacestat and 55.7% for varegacestat. The company plans a Phase III trial for 2027, with a regimen of 450 mg weekly followed by 300 mg every two weeks. Parabilis has aligned with the FDA on the trial design, aiming for a broad patient population and progression-free survival as the primary endpoint.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PBLS (Parabilis Medicines, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PBLS coverage spans financial news, technology and market movers.
Canaccord Genuity initiated coverage of Parabilis Medicines with a Buy rating and a $39 price target, implying a 36.7% upside from the Nov 6 close of $28.53.
The lease expansion and rent abatement could improve the company's operational flexibility and reduce cash outflows, modestly supporting the stock.
Positive clinical data and clear regulatory path suggest upside for PBLS.
Positive Phase II data could lift the stock.
Strong early efficacy and regulatory alignment de‑risk the upcoming Phase 3 trial.
AlphAI scores every news story that mentions PBLS with an AI model for sentiment and relevance, and aggregates insider trades from Parabilis Medicines, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Canaccord Genuity initiated coverage of Parabilis Medicines with a Buy rating and a $39 price target, implying a 36.7% upside from the Nov 6 close of $28.53.
Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 30, 2026, Parabilis Medicines, Inc. (the “Company”) and LS 400/500 CDP, LLC (the “Landlord”) entered into a Third Amendment of Lease (the “Amendment”), which amends certain provisions of that certain Lease Agreement
Parabilis reported a 72% response rate for its drug, comparing it to published data of 41% for nirogacestat and 55.7% for varegacestat. The company plans a Phase III trial for 2027, with a regimen of 450 mg weekly followed by 300 mg every two weeks. Parabilis has aligned with the FDA on the trial design, aiming for a broad patient population and progression-free survival as the primary endpoint.
Parabilis Medicines' [PBLS] Zolucatetide showed 72.2% ORR at week 32, 100% disease control at 450 mg or higher, with no progressions. FDA-aligned plans aim for PEDESTAL trial initiation in H1 2027 and top-line data in 2029, according to the company's investor update.
Parabilis Medicines (PBLS) reported 72.2% ORR and 100% DCR in Phase 1/2 zolucatetide data for desmoid tumors. FDA aligned on Phase 3 trial design, starting H1 2027, with topline results expected in 2029. Company to host investor webcast on October 24, 2026.
H.C. Wainwright initiated coverage on Parabilis Medicines (PBLS) with a buy rating and $40 price target, citing de-risked lead asset, niche markets, and pipeline upside. The stock trades at $27.85, with InvestingPro suggesting overvaluation. PBLS uses AI and physics-based modeling for drug development, with a collaboration with Regeneron validating its platform.
Disc Medicine (IRON) surged 38.86% to $78.93, leading healthcare gains. Cleveland-Cliffs (CLF) rose 16.34% to $14.10 in materials. Almonty Industries (ALM) fell 10.17% to $8.83, among notable decliners.
Parabilis Medicines (PBLS) gained 13% after announcing an upcoming trial readout for its lead drug, zolucatetide, in desmoid tumors. The company is backed by Regeneron (REGN).
Parabilis Medicines (PBLS) began a dose-ranging study of zolucatetide in FAP patients, showing early reductions in polyp burden. The Phase 1/2 trial is ongoing, with more data expected in 2027. Zolucatetide is also being evaluated for other tumors. FAP has no approved systemic therapies.
MediciNova (MNOV) +36%, AbCellera (ABCL) +9%, Parabilis (PBLS) +10%, Haemonetics (HAE), and NeoGenomics (NEO) reached 52-week highs on Sept 17, 2026. MNOV's MN-166 is in Phase 3 trials. ABCL's ABCL635 met primary endpoint in Phase 2. PBLS raised $770.5M in IPO. HAE reported 5.6% revenue growth. NEO's RaDaR ST test got Medicare/Medicaid coverage, revenues up 11%.
